Physician profile
Syed M Raza
NPI 1841220241
$1,414.69
in general payments reported to CMS, 2019-2025
14 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $195 · 2021: $237 · 2022: $145 · 2023: $187 · 2024: $135 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $429.41 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $311.97 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $99.55 | 2024 | Uzedy, Austedo Xr |
| Abbvie INC. | $92.24 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $78.43 | 2025 | Cobenfy |
| Indivior INC. | $77.21 | 2023-2024 | Perseris, Sublocade |
| Lundbeck LLC | $72.97 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.10 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $57.05 | 2021-2023 | Rexulti, Abilify Maintena |
| Astellas Pharma US INC | $50.30 | 2025 | Vyloy |
| Bioxcel Therapeutics, INC. | $25.92 | 2023 | Igalmi |
| Vanda Pharmaceuticals INC. | $19.46 | 2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $18.02 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.